Market reactionShares rose 10% on Nov 6.
Zura Bio is a clinical-stage company developing tibulizumab, an antibody that blocks IL-17 and BAFF, for hidradenitis suppurativa, systemic sclerosis and polymyalgia rheumatica; it is not approved.
Zura's case rests on tibulizumab, a bispecific antibody targeting IL-17 and BAFF, with Phase 2 results still ahead. TibuSHIELD in hidradenitis suppurativa remains on track for Q4 2026, followed by TibuSURE in early diffuse cutaneous systemic sclerosis in the first half of 2027. Cash of $187.7 million at September 30, 2026 is expected to support planned operations through at least the end of 2028. PMR expansion is planned, while torudokimab and crebankitug remain under evaluation.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: TibuSHIELD shows a clear benefit in hidradenitis suppurativa
Does tibulizumab deliver a clinically meaningful benefit in hidradenitis suppurativa with acceptable safety?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Tibulizumab readouts remain on schedule; cash runway guidance unchanged
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Obesity, diabetes and heart disease, Skin diseases, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
13 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.